Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
AZZ Inc. (NYSE:AZZ) shares declined 10.53 percent to close at $38.56 a share Friday. The stock traded between $36.20 and $40.35 on volume of 756,791 shares traded. The company reported a net income of $14.5 million, or $0.57 per diluted share, for the first quarter of fiscal 2014, compared to net income of $16 million, or $0.63 per diluted share, a year ago.
Get more information on AZZ and free access to the in-depth equity report at: www.FiveStarEquities.com/AZZ
Clean Diesel Technologies, Inc. (NASDAQ: CDTI) shares plunged 35.29 percent to close at $1.21 a share Friday. The stock traded between $1.15 and $1.21 on volume of 1.26 million shares traded. The company announced the pricing of an underwritten public offering 1.6 million shares of common stock at $1.245, a discount of roughly 33 percent to Thursday’s closing price. Shares of Clean Diesel Technologies have fallen approximately 44.2 percent year-to-date.
Get more information on Clean Diesel Technologies and free access to the in-depth equity report at: www.FiveStarEquities.com/CDTI
Dana Holding Corporation (NYSE: DAN) shares spiked 5.77 percent to close at $19.26 a share Friday. The stock traded between $18.86 and $19.76 on volume of 8.15 million shares traded. The company announced that its Board of Directors has expanded its common share repurchase program to up to $1 billion. Shares of Dana Holding have gained approximately 23.4 percent year-to-date.
Get more information on Dana Holding and free access to the in-depth equity report at: www.FiveStarEquities.com/DAN
Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares soared 24.8 percent to close at $7.95 a share Friday. The stock traded between $6.14 and $8.20 on volume of 9.73 million shares traded. The company announced that Roche’s Herceptin, which uses an enzyme developed by Halozyme, received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Shares of Halozyme Therapeutics are up approximately 18.5 percent year-to-date.
Get more information on Halozyme Therapeutics and free access to the in-depth equity report at: www.FiveStarEquities.com/HALO
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]